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Antilymphocytic serum (ALS) is now known to have a pronounced immuno- 
suppressive effect on animals into which it is injected (1-4). In certain experi- 
ments during prolonged treatment with ALS in dogs and monkeys some ani- 
mals  have  died  with  symptoms  of  acute  viral  infections  (3,  5).  It  has 
been suggested (6) that these infections were caused by a provocation of occult 
viruses brought about by abolition of an antiviral immunity in the hosts. How- 
ever, direct experimental data supporting such a  theory have  hitherto been 
lacking. 
The question of whether it is possible to provoke latent virus infections by a 
suppression of the immune mechanism of the host obviously has both theoretical 
and  practical implications.  It would  therefore seem necessary to investigate 
the matter. The mouse-lymphocytic choriomeningitis (LCM) virus system is 
ideal for this  purpose. After recovery from an LCM virus infection of adult 
mice the virus often persists in the mice for a long time, probably for the rest 
of the life of the animals (7).  1 The mice are perfectly healthy, have moderate 
high titers of complement-fixing antibodies, and are immune against reinfection. 
In spite of this, trace amounts of virus may occasionally be found in the blood 
and moreover in certain organs, such as the kidneys, the presence of virus can 
be demonstrated regularly a year or more after the infection. A perfect balance 
between the LCM virus and its host seems therefore to have been established. 
It is the purpose of this report to present data which show that prolonged treat- 
ment  with  ALS  can  tip  such  a  balance  in  favor  of  the  virus  and  pro- 
voke a viremia with high titers of virus. No correlation between  the titers of 
complement-fixing antibodies and  the  blood  virus  titers  has,  however,  been 
demonstrated. 
*The Institute  of Tumour  Virus Research is  supported by  grants from the  "Einar 
Willumsen's Memorial Fund" and the "Danish Cancer Society." 
The investigations are  also supported by grants from "Daell  Fonden" and  "Statens 
almindelige Videnskabsfond." 
1  Larsen, J. H. 1967. Personal communication. 
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Materials and Methods 
Anirnals.--The  mice were highly inbred AKR mice raised at our institute. The rabbits 
used for the preparation of antilymphocytic serum and control sera were noninbred grey and 
white rabbits obtained commercially. 
Antilymphocytic serum was prepared from rabbits by a modification of the method described 
by Gray et al.  (8)  and the procedure used is described in detail by Lundstedt and Volkert 
(9).  The cell suspensions used for immunization were a  mixture of lymph nodes and spleen 
cells from normal female mice. 25 X  106 cells of this mixture in a volume of 0.1 ml emulsified 
with an  equal  volume of complete Freunds adjuvant were injected into  each of  the  foot- 
pads of the recipients. 4 wk later booster injections of 100 X  l0  s lymph node and spleen cells 
without adjuvant were given intraperitoneally on 3 consecutive days, and 1 wk after the last 
injection the rabbits were bled. The serum was collected and stored at -20°C  after addition 
of merthiolate 1:10,000.  The rabbits were bled several times but booster injections of  100 X 
106 cells were always given 1 wk prior to bleeding. The serum prepared in this way is strictly 
speaking an antiserum against all the different cells in the preparation, but for the sake of 
simplicity it will be referred to as antilymphocytic serum (ALS). 
Control sera were sera from normal rabbits stored as described for the ALS. 
Potency tests of the ALS were carried out by in vitro cytotoxic tests and by determining 
the effect in vivo on the number of the blood lymphocytes. The cytotoxic tests were performed 
according to  the method described by Gofer and O'Gorman (10).  Routine tests gave cyto- 
toxic indices of approximately 0.25 with cell concentrations of 10 X  106 cells and 0.25 ml of 
ALS injected intraperitoncally into 20-g mice caused a fall in the cell count to approximately 
one third of the original values within 150 rain. 
LCM virus strain originated from Dr. Tranb, Germany, and has been used in this laboratory 
for many years (11). The virus was passed when necessary by intraperitoneal inoculation of 
mice.  The virus preparations consisted of a  10%  spleen suspension from infected mice and 
was stored at -70°C. The virus titrations were carried out as previously described (12). Ordi- 
nary white Swiss mice were used for the test. The end points were calculated in accordance 
with the method of K~rber (13) and expressed as log 10 LD~0/0.03 ml. When only one of the 
inoculated mice died after the 7th day of the observation period the titer is expressed as trace. 
Blood virus titers were determined on whole blood taken from the extraocular venous plexus. 
Complement-fixing antibodies were titrated as described previously (14). The method was 
altered only in that the antigen used was prepared from spleens of tolerant virus-carrier mice. 
The end points of the titrations were the last tubes showing less than 50% hemolysis. The 
sera were stored at 4°C and the tests were carried out once a week. 
EXPERIMENTAL 
Mice which have become immune to the LCM virus by either a natural infection or by an 
artificial  infection have been employed. The natural infection was brought about in mothers 
nursing infected babies. For the purpose of studying tolerance to the virus in this laboratory 
newborn babies are routinely injected with the LCM virus. The babies treated in this way 
develop a  tolerant virus infection, excrete virus in great amounts,  and contaminate their 
mothers (11). This contamination has never been seen to cause an overt disease in the mothers. 
However, at the time they are separated from their offspring, usually 6-8 wk after the babies 
are born, they have developed a  strong immunity to the virus. They are highly resistant to 
reinfections and  the blood contains high  titers of complement-fixing antibodies. Artificial 
infections are also routinely used in this laboratory in order to produce immunization. This is 
achieved by intraperitoneal injections of sublethal doses of virus into adult female mice. 4 wk 
after such injections these mice have also developed a strong immunity to the virus and have •OGENS  VOLKERT  AND  CLAUS  LUIVDSTEDT  329 
high complement-fixlng antibody titers. In both groups the virus has a  tendency to persist 
as described in the introduction. However, no spontaneous provocation of the virus has ever 
been observed. 
Experiment I.-- 
In the first series of experiments 24 mothers of infected babies were employed.  All had 
nursed their babies for 7-8 wk and were used for the experiment within a week after the babies 
had  been removed. The blood of each mouse was tested  individually for virus in  dilutions 
of  10t-104 and for complement-fixing antibodies in dilutions of 8-1024. The mice were then 
divided at random into three groups of eight mice each. 
In group A all mice received 0.25 ml of ALS intraperitoneally six times a  week for 7 wk. 
On days 10, 20, 27, 34, 42, 53, and 74 individual blood samples were tested for virus and com- 
plement-fixing antibodies in the dilutions mentioned above. The first 3 wk of  treatment were 
well tolerated, but from then on all mice began to look ill and two died between the 34th and 
42th day. After the ALS injections were discontinued on the 44th day of the experiment, the 
remaining mice recovered slowly. 
Groups B and C comprised the control groups. The mice in group B received normal rabbit 
serum intraperitoneally in amounts of 0.25 ml following the same schedule as described for 
group A. The treatment was well tolerated throughout the experiment. The mice in group C 
did not receive any treatment. Blood tests for virus and complement-fixing antibodies were 
performed individually on each mouse in both groups on the same days as the mice in group 
A were tested. 
The virus titration results for all three groups are given  in Table I. Where 
those mice that received ALS are concerned it is seen that none of  them had 
detectable virus in their blood at the beginning of the experiment. On day 10 
and day 20 after the ALS injections were initiated, occasionally mice could be 
found with trace amounts of virus in the  blood  but  as  it  is  apparent  from 
the control group C this is not more than is to be found in untreated immune 
mice. However, during the last part of the ALS treatment the situation changed 
and all mice developed a  dear-cut viremia with virus titers varying from 1.3 
to 3.5. In none of the mice was the viremia detected earlier than 27 days after 
the serum injections were started, and in some it was even later. In two mice 
the viremia was detected in only one blood sample.  In four mice the  viremia 
lasted until the ALS treatment was discontinued and then disappeared within 
10  days. One mouse,  the  one with the highest  blood virus titer,  had a  more 
prolonged viremia than the others, but even in this case practically all the virus 
in the blood had disappeared when the last test was done. As mentioned earlier 
two of the mice had died during the experiment and we only know that viremia 
developed. 
In both control groups B  and C  trace amounts of virus could be found in 
only two mice during the whole experimental period; in none of the others was 
virus detectable in the blood. 
Where  the complement-fixing  antibodies are  concerned  it  is apparent  from 
Table II that in untreated  mice the  titers at the  beginning of the  experiments 
varied about eightfold from mouse to mouse and about half of the animals had 330  LYMPHOCYTIC  CHORIOMENINGITIS  VIRUS  INFECTIONS 
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a  titer of 128. In some of the mice in group C  that did not receive  any treat- 
ment the antibody titers showed a  tendency to decline in the following weeks 
but no great variations were seen. The results for group B very closely resembled 
those in group C and are therefore not recorded. The mice in group A, however, 
showed an antibody pattern that was clearly different from the control groups. 
TABLE II 
LCM Complement-Fixing Antibody Titers o/Mice Immunized by a Natural Infection 
and Afterwards Treated with A LS 
Animal groups 
Experimental group A 
receiving ALS 
Mouse 1 
"  2 
"  3 
"  4 
"  5 
"  6 
"  7 
"  8 
Control group C un- 
treated 
Mouse 1 
"  2 
"  3 
"  4 
"  5 
"  6 
"  7 
"  8 
Antibody  titers 
days  0  10  20  27  34  42  53  74 
128 
32 
128 
32 
64 
128 
64 
64 
256 
128 
256 
512 
256 
256 
64 
128 
ALS treatment 
1024 
32 
128 
16 
1024 
1024 
-> 1024 
~1024 
128 
128 
64 
64 
64 
256 
128 
128 
1024 
512 
128 
32 
1024 
256 
1024 
2048 
512 
128 
64 
32 
64 
256 
128 
128 
256 
512 
256 
32 
256 
512 
256 
512 
1024 
128 
64 
128 
32 
128 
64 
128 
512  256  512 
256  128  256 
512  256  256 
--  512  512 
256  256  512 
512  256  512 
128  256  512 
32  64  256 
32  32  -- 
128  32  64 
32  16  32 
--  128  128 
128  32  64 
128  64  128 
--, not done. 
In the  beginning of  the experiment a  depression of  the  antibody titers  was 
demonstrable in three of the mice whereas the titers seemed to remain constant 
in the  others.  On day 20,  however, before any viremia could be detected,  a 
steep rise in titers occurred in five of the eight mice. Moreover, an increase in 
antibody titers also occurred in two other mice, but this increase came later 
and was less pronounced. After this rise most of the antibody titers remained 
high for about a week or two and then declined to the original level. One mouse 
had  an antibody pattern which differed from the  others.  In this mouse  the 332  LYMPHOCYTIC  CHORIOMENINGITIS  VIRUS  INFECTIONS 
antibody titer was also depressed in the beginning but, contrary to what hap- 
pened in the others, the titer never rose again. The mouse, however, could not 
be followed for a very long period as it died between the 34th and 42nd day of 
the ALS treatment. 
Experiment H.-- 
In the second series of experiments artificially infected mice were employed. The ages of 
the mice  were between 21/6 and 3~ months. All mice were infected with LCM virus by intra- 
peritoneal injections of sublethal doses of virus and then divided at random into three groups 
of eight mice each (groups D, E, and F). To make certain that an infection had been estab- 
lished, the blood of each mouse in all three groups was tested individually  for virus in dilutions 
of 10ml0  * and for eomplement-fix4ng  antibodies in dilutions of 8-1024 6 days after the virus 
inoculation. The titration results showed that all 24 mice had viremia with virus titers varying 
from 1.0-1.8 and none of them had complement-fixing  antibodies. To ascertain that an immun- 
ity developed 20 and 29 days after the virus inoculation all mice in all groups were tested again. 
The samples on both these days showed that none of the mice had any detectable virus in 
their blood and that all of them had complement-fixing  antibodies in fiters varying from 64 
to 256. 
When the blood samples had been collected on day 29 after the virus inoculation the ALS 
experiment was begun. 
In the experimental group D all mice were injected intraperitoneally with 0.25 ml of ALS 
six times a week for 7 wk as described for group A in the foregoing  experiment. Blood samples 
for virus and antibody titrations were collected individually following a schedule which was 
also identical with the one used for group A. 
Groups E and F comprised the control groups. The mice in group E received normal rabbit 
serum intraperitoneally in the same amounts and on the same days the mice in group D were 
injected. The mice in group F were left untreated. Blood samples from the mice in both con- 
trol groups were collected and tested individually for virus and antibodies on the same days 
as those from group D. 
As was the case in group A, the mice in group D which received ALS tolerated 
the treatment well for about 3 wk, but from then on all of them became ill and 
two died during the 4th and the 5th wk respectively. Of the remaining six mice, 
two  died after  the ALS  injections were  discontinued, but  the  other four re- 
covered slowly. The control mice receiving normal serum and those which were 
left untreated remained healthy throughout the experiment. 
The data from the virus titrations are recorded in Table III. It is seen that 
the  blood virus titers  of  the  ALS-treated mice resembled  those  obtained in 
Experiment  I.  During the  ALS  treatment  all  mice  in  group  D  developed 
viremia. However, as a  whole this viremia developed earlier than in the first 
experiment. As many as four out of the eight mice had rather high virus titers 
10 days after the ALS injections were begun. Moreover five out of the eight 
mice reached virus titers of 2.8 or higher and one a  titer as high as 4.5. When 
the  ALS treatment was  discontinued the  virus titers  declined. In two  mice 
which had developed high titers the viremia lasted during the first  12  days, 
and even on the 74th day one mouse showed a titer of 1.8. MOGENS  VOLKERT  AND  CLAUS  LUNDSTEDT  333 
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From Table III it is also apparent that in the control mice only trace amounts 
of virus could be demonstrated. In the untreated group this was seen on only 
three occasions whereas it was a more frequent observation in the group which 
received normal rabbit serum. 
In contrast to what had been observed in the first experiment the ALS treat- 
ment in this investigation did not influence the antibody level. Neither a depres- 
sion nor the subsequent increase in titer could be  demonstrated. Throughout 
the whole experimental period there was no significant  difference in the anti- 
body titers obtained in the ALS-treated groups and the  control groups. The 
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FIG. 1.  The effect of ALS treatment on a  mouse which had been vaccinated with llve LCN[ 
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mean titer for all groups remained at a level of about 128 from the beginning 
to the end of the experiment. 
The data from the virus titrations and the antibody titrations obtained in 
one of the ALS-treated mice are recorded graphically in Fig.  1. 
DISCUSSION 
The results presented demonstrate clearly that intensive and prolonged ALS 
treatment  of mice can provoke a  latent LCM virus infection.  Highly inbred 
mice have been employed in these experiments. Nevertheless, the effect of the 
ALS on the blood virus titer level varied greatly from mouse to mouse. How- 
ever, it is noteworthy that in none of the ALS-treated mice did the treatment 
fail to cause a  multiplication of the occult virus. This result was achieved in 
spite of the fact that all the mice in which it happened were highly immune MOGENS  VOLKERT  AND  CLAUS  LUNDSTEDT  335 
to the virus at the time the ALS treatment was begun. In addition to the indi- 
vidual variations there was a clear difference between the results obtained in 
the two groups of immune mice which received ALS. Taken as a  whole the 
viremia developed earlier and the blood virus titers were higher and remained 
high for a longer period after the discontinuation of the treatment in the mice 
employed in the second experiment than in those in the first experiment. The 
mice used in the two experiments differed at the beginning of the ALS treat- 
ment by the way the immunization and the latent virus infection were brought 
about.  In  the  first experiment the mice employed were mothers of infected 
babies and these mice had had a natural infection. The mice in the other group 
were infected artificially by intraperitoneal injection of virus.  The antibody 
levels in the two groups of mice were practically the same at the beginning of 
the  experiment. However,  on many  previous  occasions in  this  laboratory 
the immune status of the two kinds of mice have been compared with respect 
to the immunity which can be conferred to tolerant virus carrier mice by trans- 
plantation  of lymphoid cells from the  immune  donors.  In such experiments 
it has repeatedly been found that the potency of the ceils from the immune 
mothers is greater than that of the cells from artificially infected mice (12). 
Theoretically it  seems  logical to  expect  that  the  animal  with  the  strongest 
immunity also should be the one with the highest resistance to ALS. This expec- 
tation was confirmed by our ALS experiments, provided that one judges the 
immunity by potency of lymphoid cells and not by the antibody level. 
Where  the  influence  on  the  virus  of  complement-fixing  antibodies  is 
concerned, earlier experimental results from this laboratory (9, 15-17) strongly 
suggested that these antibodies most probably have no influence on the virus. 
The data presenl ed in this paper support this view. The results clearly show 
that the viremia develops in spite of constant and even increasingly high titers 
of complement-fixing antibodies  and  the  elimination  of virus  also  seems  to 
occur independently of these antibodies. Moreover, the resistance to ALS seems, 
as pointed out above, to be related to the "cellular" immunity and not to the 
kind of immunity which can be determined by a measurement of the comple- 
ment-fixing antibody level. The role of neutralizing antibodies to LCM virus 
is not yet fully known. However, in this respect it must be pointed out that 
no one has been able to demonstrate with certainty the presence of these anti- 
bodies in either artificially or naturally LCM-infected and immune mice (7, 14, 
18-20). The search for another humoral factor, interferon, which might influ- 
ence the  LCM virus  has  also  failed  (14).  We  feel  that  at  present  all  the 
available  data  support  the  view  expressed  in  an  earlier  article  from  this 
laboratory that a  direct cellular activity (a cellular immunity?) plays a  very 
important role in the LCM infection in mice. This hypothesis is also supported 
by what has been learned about the action of ALS in other experiments. Levey 
and  Medawar  (4)  have  pointed  out  that  ALS  apparently  inhibits  cellular 336  LYMPHOCYTIC  CHORIOMENINGITIS  VIRUS  INFECTIONS 
responses preferentially and it has also been shown that ALS has a very pro- 
nounced  effect on  the  "host  versus  graft"  reaction  and  delayed sensitivity 
reactions (21)--phenomena which are believed to be entirely cell bound.  On 
the other hand the effect of ALS on a  preexisting humoral antibody level is 
not very strong  (2,  22)  or, as shown in our experiments, in many cases not 
demonstrable at all. Very recently one of us  (Lundstedt) has obtained some 
preliminary experimental results in vitro which might indicate that a reaction 
occurs between LCM  immune  lymphoid cells and  ordinary L  cells infected 
with LCM virus. The interaction between these two types of cells seems to 
cause the death of the infected cells. It is well known that an in vitro reaction 
like  this  occurs between immune lymphoid cells and  tumor cells containing 
new cellular antigens (23-26) and some authors believe that this phenomenon 
plays an important role in the elimination of malignant cells in vivo (24). If 
Lundstedt's experiments are confirmed the elimination of LCM  virus-infected 
cells in vivo by the same mechanism would be a tempting hypothesis. 
The provocation of latent LCM infections by treatment with ALS strongly 
suggests that other latent virus infections can be provoked in the same way. 
The assumption  made  by other investigators  that  their animals  which died 
during an ALS treatment were killed by a provocation of occult viruses seems, 
therefore, very probably correct. In our experiments the virus titers declined 
again when the injections of ALS were discontinued. However, we know from 
other experiments (9)  that  a  protracted tolerant LCM  infection can be pro- 
duced in mice when the infection takes place under cover of ALS. Tolerant 
LCM virus infections might therefore also be the result when latent LCM virus 
infections are provoked by ALS and the treatment is continued longer than 
we have done. Such very prolonged ALS treatments are often given in kidney 
transplantation experiments. As we already have mentioned, the provocation 
of virulent viruses might mean the immediate death of the subject under treat- 
ment. However, one cannot avoid speculating what would happen if the virus 
which is provoked is a tumor virus and the provocation causes a tolerant infec- 
tion. 
A  curious observation in our experiments was  that  in some mice the ALS 
treatment  temporarily seemed  to  stimulate  the  production  of complement- 
fixing antibodies. This happened, however, only in one group of mice. In all 
groups some variations in antibody titers were noticed, but the rise observed 
in some of the ALS-treated mice was so large that it can hardly be incidental 
or due to experimental errors. 
The ALS effect on virus infections might have other and important implica- 
tions for virus research. It might be  possible under cover of ALS to cultivate 
viruses in animals in which these viruses normally  do not mulfiplicate. Some 
evidence in  support  of this hypothesis has already been presented by  other 
investigators (27). In spite of the fact that the results obtained hitherto in this 
respect are only preliminary they are very suggestive. MOGENS  VOLKERTANDCLAUS  LUNDSTEDT  337 
SUMMARY 
The  hypothesis  that  treatment  with  antflymphocytic  serum  (ALS)  can 
provoke latent virus infections has been investigated. 
In adult mice infections with sublethal doses of LCM virus usu,~lly  result 
in the development of immunity to the virus and at the same time to a  pro- 
longed latent infection. 
In  the  experiments described  an  intensive  treatment with  large  doses  of 
ALS  was given to mice which  had recovered  from LCM virus infection.  At 
the beginning of the treatment the mice had high fiters of complement-fixing 
antibodies in their blood and no detectable virus. The data presented show that 
in spite of the immunity the ALS treatment provoked the occult virus and led 
to the development of viremia in all the treated mice. In some, very high virus 
titers  were  demonstrable.  When  the  ALS  treatment  was  discontinued 
the viremia disappeard again. 
In most of the mice the ALS did not suppress the complement-fixing anti- 
body titers and in some there was even a considerable increase in titer. In such 
cases the increases in virus titers and in antibody titers were closely related to 
one another. These results demonstrate once again that the complement-fixing 
antibodies to the LCM virus in mice probably do not influence the virus. 
The authors are indebted to Mrs. B. H~jer Simonsen for skillful technical assistance. 
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